Graft-versus-host disease (GVHD) is the most lethal complication after allogeneic bone marrow transplantation (allo-BMT). Current approaches to prevent GVHD rely on donor lymphocyte/T cell depletion or general immunosuppression, leading to opportunistic infections and cancer relapse. Tolerogenic dendritic cells can induce regulatory T cells (Tregs) with the ability to suppress inflammation and prevent transplant rejection, making them an attractive cellular therapy to control GVHD. Active vitamin D (1α,25-dihydroxyvitamin D 3 ; 1α,25(OH) 2 D 3 ) promotes the generation of tolerogenic dendritic cells (1,25D 3 -DCs). This study aimed to determine the ability of ex vivo generated 1,25D 3 -DCs to trigger the expansion of Tregs that are able to control lethal xenogeneic GVHD in humanized NOD/LtSz-Prkdc scid IL2rγ tm1Wjl (NSG) mice. We demonstrate that 1,25D 3 -DCs express lower levels of HLA-DR and costimulatory molecules, such as CD80 and CD86, and produce higher levels of IL-10 and TNF-α and lower amounts of IL-12, compared to vehicle-treated DCs. Moreover, these cells express increased levels of various co-inhibitory molecules such as PD-L1 and ILT-3 and the glycoprotein CD52 that is known to suppress T cell activation. Consequently, 1,25D 3 -DCs are poor stimulators of alloantigen-primed T cells, but foster the generation of antigen-specific suppressive Tregs. When adoptively transferred in humanized NSG mice, these 1,25D 3 -DC-induced Tregs delayed GVHD caused by the co-transferred autologous human peripheral blood mononuclear cells (PBMCs). These results indicate that 1,25D 3 -DC-induced Tregs can inhibit xenogeneic GVHD and maintain their immunomodulatory function under conditions of inflammation.
Introduction
Allogeneic bone marrow transplantation (allo-BMT) has been exploited as a curative treatment for hematological malignant and nonmalignant diseases since the 70 s [1] . The alloreactivity of these cells against human leukocyte antigen (HLA) mismatches and minor histocompatibility antigens can trigger life-threatening graft-versus-host disease (GVHD) [2] . Recent studies suggest that an imbalance in effector (Teff) and regulatory T cell (Treg) reconstitution after allo-BMT can amplify alloreactivity and promote GVHD.
Vitamin D 3 is a fat-soluble hormone that can be acquired from food or be synthesized in the skin upon ultraviolet-B radiation. In addition to its classic role in calcium/phosphate and bone homeostasis, 1α,25-dihydroxyvitamin D 3 (1α,25(OH) 2 D 3 ), which is the active metabolite of vitamin D 3 , has been identified as a potent natural modulator of innate and adaptive immunity [3] . In dendritic cells (DCs), generated from bone marrow precursors or peripheral blood monocytes, 1α,25(OH) 2 D 3 interferes with the differentiation and maturation processes [4] , locking DCs in a tolerogenic state [5] . DCs generated in the presence of 1α,25(OH) 2 D 3 (1,25D 3 -DCs) maintain CD14 expression, express little CD1a, show reduced expression of antigenpresenting (e.g. HLA-ABC and -DR) and costimulatory molecules (e.g. CD80, CD86) and diminished secretion of stimulatory cytokines (e.g. interleukin (IL)-12, IL-23) that are known to regulate the polarization of Teff cells [6] [7] [8] . Moreover, the expression of inhibitory molecules, including programmed death-ligand (PD-L) 1, PD-L2, and immunoglobulin-like transcript (ILT)-3 and -4, is upregulated and the production of regulatory cytokines like IL-10, transforming growth factor (TGF)-β and tumor necrosis factor (TNF)-α is enhanced [6, 9, 10] . As a result, 1,25D 3 -DCs influence T cell behavior inducing hyporesponsiveness and shifting T cell polarization from T helper (Th)1-and Th17-mediated inflammatory responses towards Treg responses [8] [9] [10] . In addition to these effects, 1α,25(OH) 2 In rodents, adoptively transferred tolerogenic DCs can efficiently suppress lethal acute GVHD by the in vivo generation of inducible Tregs (iTregs) [11] [12] [13] [14] . However, high numbers of these cells are needed to reduce the incidence and severity of GVHD and so far, complete protection from GVHD has never been achieved. In addition, a major fear is the reversal of the ex vivo induced tolerogenic phenotype when exposed to the in vivo pro-inflammatory environment of the host, resulting in immunogenic DCs that could induce Teff cells, rather than Tregs. Thus, intervention strategies that generate stable tolerogenic DCs that induce Tregs with superior suppressive ability would be advantageous to control GVHD as well as prevent transplant rejection or treat autoimmunity. Although rodents continue to be important in vivo models for studying the human immune system, we currently recognize the potential limitations of generalizing data from mice to humans. The model of NOD/LtSz-Prkdc scid IL2rγ tm1Wjl (NSG) mice allows the study of an extreme form of GVHD, namely a xenogeneic GVHD, when human immune cells are infused.
In the current study, we explored whether 1,25D 3 -DCs can induce suppressive Tregs that are able to prevent lethal xenogeneic GVHD in NSG mice infused with human peripheral blood mononuclear cells (PBMCs).
Materials and methods

Ex vivo generation of human monocyte-derived 1,25D 3 -DCs
Human monocytes were freshly isolated and differentiated into DCs as previously described [6] , with the approval of the ethics committee (S-number 52679) of the University hospital of Leuven (UZ Leuven, Leuven, Belgium). In brief, PBMCs were isolated by Lymphoprep gradient centrifugation (Alere Technologies AS, Oslo, Norway) from blood from healthy donors. Monocytes were purified from PBMCs by positive selection using the CD14 Microbeads Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer's protocol. Isolated monocytes were cultured in differentiation medium containing 500 IU/ ml human recombinant IL-4 (Gentaur, Kampenhout, Belgium) and 800 IU/ml human recombinant GM-CSF (Gentaur). Medium and cytokines were refreshed on day 3. On day 6, maturation was induced in the presence of 800 IU/ml GM-CSF (Gentaur), 100 ng/ml LPS (Sigma-Aldrich, St. Louis, MO, USA) and 1,000 IU/ml human recombinant IFN-γ (Roche, Basel, Switzerland). To obtain 1,25D 3 -DCs, 10 −8 M 1α,25(OH) 2 D 3 (Sigma-Aldrich) was added at day 0 and day 3. Similar dilution of ethanol was used as vehicle control.
Flow cytometry analysis of surface markers on human DCs
Mature vehicle-treated and 1,25D 3 -DCs were analyzed for their surface marker expression using flow cytometry. DCs were pretreated with Fc block (anti-CD16/CD32) and subsequently labelled with the following conjugated antibodies: CD1a, CCR7, CXCR3 (from BioLegend, San Diego, CA, USA), CD14, HLA-DR, PD-L1, ILT-3 (from Thermo Fisher Scientific/ eBioscience, San Diego, CA, USA), CD80, CD86 (from BD Biosciences, San Jose, CA, USA), CD52 (Bio-Rad, Hercules, CA, USA). Doublets were excluded based on signal height and widths. Dead cells were stained by Zombie Yellow/Aqua Fixable Viability Kit (BioLegend) according to manufacturer's guidelines and excluded from analysis. Samples were acquired on a Gallios ™ Flow Cytometer (Beckman Coulter) and analyzed with the FlowJo software (TreeStar, Ashland, OR, USA).
Cytokine production in DC cultures and DC:T cell co-cultures
The V-plex Proinflammatory Panel 1 Human kit from MesoScale Discovery (Rockville, MD, USA) was used according to the manufacturer's instructions for the quantitative detection of IL-12p70, IL-10 and TNF-α secreted in the DC culture supernatant and similarly the secretion of IFN-γ and IL-10 in the DC-T cell co-culture. FlowJo software (TreeStar).
Measurement of indoleamine-2,3-dioxygenase (IDO)
Induction of antigen-specific Tregs and suppression assay
T cell lines were induced as described previously [10] . In brief, CD4 + T cells were isolated from PBMCs using the Human CD4 + T cell Isolation Kit (Miltenyi Biotec), according to manufacturer's specifications. 1 × 10 6 purified CD4 + T cells were co-cultured with vehicletreated and 1,25D 3 -DCs from an haplo-identical donor at a 1:10 DC:T cell ratio in IMDM (Thermo Fisher Scientific/Gibco) with 10% human serum (Biowest, Nuaillé, France). After 5 days, T cells were recovered and rested for 2 days in the presence of 10 ng/ml IL-7 and 5 ng/ml IL-15 (both from Genscript, Nanjing, China). On day 7 after primary stimulation, the CD4 + T cells were restimulated under the same conditions. T 
Xenogeneic graft-versus-host disease model
NOD/LtSz-Prkdc scid IL2rγ tm1Wjl (NSG) mice were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA) and inbred in the animal facility of KU Leuven (Leuven, Belgium). Housing of all mice occurred under semi-barrier conditions and animals were fed sterile food and water ad libitum. Handling of mice and experimental procedures were performed in accordance to guidelines of the institutional animal care and use committee of the KU Leuven (project number ECD 221/ 2013). Xenogeneic GVHD was induced as described previously [15] . In brief, NSG mice received total body irradiation with 1.5 Gy one day before intravenous injection of purified single-donor human PBMCs (3 × 10 6 ). Simultaneously, PBS or autologous DCs (0. 
Statistics
The normality of all datasets was tested. When data was normally distributed, either unpaired Student's t test or ANOVA with Sidak's post-test for multiple comparison was used. When data was not normally distributed, statistical significance was determined using the Mann-Whitney U test or the Kruskal-Wallis test with subsequent Dunn's post-test. Differences in survival rates were assessed using the MantelCox Log-rank test. All statistical analyses were performed using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). Significance was defined as *p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001.
Results
1α,25(OH) 2 D 3 treatment induces stable tolerogenic DCs capable of homing to inflammatory sites
We first studied the cellular phenotype and function of 1,25D 3 -DCs from healthy donors after an inflammatory challenge (LPS and IFN-γ). We demonstrate that even after exposure to inflammation, 1,25D 3 -DCs displayed a stable tolerogenic phenotype with reduced surface expression of the antigen-presenting molecules HLA-DR and CD1a and the costimulatory molecules CD80 and CD86 (Fig. 1) . The expression of the monocytic marker CD14 was retained in 1,25D 3 -DCs exposed to inflammation. The inhibitory molecules PD-L1 and ILT-3 as well as the newly identified tolerogenic marker CD52 [16] were increased 1.3-, 7.5-and 6.4-fold, respectively, at the cell surface after 1α,25(OH) 2 D 3 treatment, a general feature of tolerogenic DCs [17] . Moreover, surface expression of CXCR3, responsible for homing to inflammatory sites, was upregulated in 1,25D 3 -DCs, while the chemokine receptor CCR7 was similarly expressed as in control cells, still allowing these cells to migrate to the lymphoid tissues (Fig. 1) . Also, the cytokine pattern of DCs was altered upon 1α,25(OH) 2 D 3 exposure with decreased IL-12p70 and elevated IL-10 and TNF-α secretion levels (Fig. 2) . Additionally, 1,25D 3 -DCs produced higher amounts of the indoleamine-2,3-dioxygenase (IDO) enzyme, although this difference was not statistically significant (Fig. 2) . Taken together, the inhibition of full maturation, coupled with decreased IL-12p70 and enhanced IL-10 and TNF-α production, hints at a superior immunoregulatory capacity of 1,25D 3 -DCs.
1α,25(OH) 2 D 3 -modulated dendritic cells induce allogeneic T cell hyporesponsiveness
To determine whether these 1α,25(OH) 2 D 3 -induced changes in DC phenotype and cytokine secretion resulted in an altered T cell stimulatory capacity, DCs were co-cultured with T cells. Unstimulated T cells have a low basal proliferation rate, which can be boosted by anti-CD3/ CD28 stimulation (Fig. 3A) . Addition of mature vehicle-treated DCs stimulated the proliferative capacity of both CD4 + and CD8 + allogeneic T cells with a respective 4-and 5-fold increase, which was reduced to at least half in the condition with 1,25D 3 -DCs. Analysis of cytokines secreted into the co-culture supernatant showed that T cells that were co-cultured with 1,25D 3 -DCs produced lower amounts of IFN-γ (Fig. 3B ) a typical Th1 cytokine, and high amounts of the tolerogenic cytokine IL-10 compared to mature vehicle-treated DCs (Fig. 3C) . Of note, with the used measuring technique, it is impossible to determine whether the IL-10 cytokine levels in the co-culture supernatant are produced by DCs or by T cells. These data show that 1,25D 3 -DCs are potent antigen-presenting cells that can suppress the activation of allogeneic Teff responses.
1α,25(OH) 2 D 3 -modulated dendritic cells induce suppressive antigenspecific Tregs and delay GVHD
Next, 1,25D 3 -DC-induced Treg lines were generated and assessed for their functional capacity. Tregs, primed in the presence of 1,25D 3 -DCs, potently suppressed the proliferation of responder T cells to allogeneic mature DCs compared to Teff cells, primed with mature vehicle-treated DCs, as evidenced by decreased proliferation and division indexes (Fig. 3D) .
Finally, we investigated whether 1,25D 3 -DCs were able to mediate immune suppression when transferred in vivo. We used a xenogeneic GVHD model induced by transferring human PBMCs into NSG mice that were co-injected with PBS or autologous, mature vehicle-treated DCs or 1,25D 3 -DCs (Fig. 4A ). All recipients of human PBMCs developed GVHD (Fig. 4B) and died between day 16 and day 72 following transplantation. In mice receiving only human PBMCs, clinical signs of GVHD including reduced weight, anemia and hair loss were evident from day 16 onwards (Fig. 4B) . No significant delay in disease occurrence or mortality was observed when control DCs were co-transferred with human PBMCs (Fig. 4B, C) . A single injection of co-transferred 1,25D 3 -DCs markedly attenuated GVHD onset to 34 days on average (ranged from day 28 until day 40), with reduced GVHD disease manifestations at a time when most PBS or vehicle DC-treated mice had died (Fig. 4C ). Mice were bled every 2 weeks after transfer to determine the presence of human cells and the in vivo induction of CD4 + CD25 + FoxP3 + Tregs by flow cytometry. Interestingly, at the first time point of 2 weeks postengraftment, a significant higher percentage of human FoxP3-expressing Tregs were present in the mice that received 1,25D 3 -DCs compared to vehicle-treated DCs or only PBMCs, while the total CD4 + CD25 + population remained equal over the different groups and over time (Fig. 4D) . However, 4 and 8 weeks post-engraftment this effect was no longer detectable. This observation indicates that 1,25D 3 -DCs are able to induce CD4 + CD25 + FoxP3 + Tregs in an in vivo setting, but that this is a transient phenomenon.
Discussion
The active metabolite of vitamin D 3 , 1α,25(OH) 2 D 3 , potently modulates the behavior of several immune cells. In DCs, 1α,25(OH) 2 D 3 induces a tolerogenic profile. As DCs play a central role in regulating the delicate balance between immunogenicity and tolerance, 1,25D 3 -DCs possess a great potential for therapeutic applications in autoimmune diseases and transplantation settings. In the current manuscript, we confirmed previous studies showing the 1α,25(OH) 2 D 3 -mediated downregulation of antigen-presentation, costimulation and pro-inflammatory cytokine production. Moreover, an increased surface expression of inhibitory molecules and tolerogenic cytokine secretion was observed. 1,25D 3 -DCs maintained a specific migratory signature upon 1α,25(OH) 2 D 3 modulation, allowing them to migrate to the lymph nodes and the site of inflammation [6, 10, [18] [19] [20] [21] [22] . Interestingly, these changes remained stable upon inflammatory challenge in vitro [10, 23] , which is crucial for in vivo applications where 1,25D 3 -DCs will have to exert their functions in a highly inflammatory environment. The elevated expression of the new tolerogenic DC biomarker CD52 [16] was validated as well.
Many microarray analyses have been performed on several cell types, including immune cell subsets, to identify direct transcriptional targets of 1α,25(OH) 2 D 3 . However, only early time points are useful to distinguish primary and secondary target genes as the full 1,25(OH) 2 D 3 -mediated transcriptional process is believed to take 2-3 h [24] . In addition, primary 1α,25(OH) 2 D 3 targets are expected to have at least one vitamin D responsive element (VDRE) in their promoter region. Therefore, establishment of the chromatin immunoprecipitation sequencing (ChIP-seq) technique allowed the study of transcriptional regulation in more detail on a genome-wide scale. For example, the CD14 gene expression has been found to be early upregulated by 1α,25(OH) 2 D 3 treatment [25, 26] . Moreover, the promoter region of CD14 comprises several VDR binding sites, confirming that CD14 is indeed a direct target of active vitamin D 3 [26] . Over the past few years, 1α,25(OH) 2 D 3 has been shown to rapidly regulate several immune genes in monocytes and DCs (e.g. CD274, CD40, CD80, HLA-DR) [16, [25] [26] [27] . With regard to the physiological actions of active vitamin D, not only the primary 1α,25(OH) 2 D 3 targets are important and secondary targets should be taken into account as well. In this regard, 1α,25(OH) 2 D 3 induces other transcription factors that could regulate the expression of secondary target genes [28] . Other mechanism of indirect regulation by 1α,25(OH) 2 D 3 include protein-protein interactions with other transcription factors, such as NF-κB in the case of IL-12 [29] , hereby preventing association with its genomic binding sites or (1,25D 3 ; grey) . The expression level of phenotypical markers HLA-DR, CD1a, CD80, CD86, CD14, PD-L1, ILT-3, CD52, CXCR3, and CCR7 was determined by flow cytometry (n = 6-12). Bar graphs represent mean fluorescence intensity (MFI) ± SEM. Each dot represents a different DC donor. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Fig. 2 . 1α,25(OH) 2 D 3 -modulated human dendritic cells secrete low levels of stimulatory cytokines and high levels of tolerogenic cytokines and markers. Secretion levels of the cytokines IL-12p70, IL-10 and TNF-α into the DC culture supernatant were measured by MSD multiplex (n = 6-11). Bar graphs represent mean cytokine levels ± SEM. Production of the enzyme IDO into DC culture supernatant was determined by ELISA (n = 6). Bar graphs represent mean IDO protein level ± SEM. Each dot represents a different DC donor. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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the induction of epigenetic changes [30] . Future ChIP-seq experiments in human 1,25D 3 -DCs will provide more insights in genomic VDR binding sites and allow better discrimination between primary and secondary targets. As a result of these aforementioned phenotypic changes, 1,25D 3 -DCs are poor T cell stimulators and simultaneously drive the induction of antigen-specific Tregs [10, 31] . Our current data indeed showed strongly reduced T cell proliferation and the generation of functional Tregs in vitro and in vivo. . The characterization of these T R 1 cells was solely based on the observation that the iTregs produced high amounts of IL-10 and was not confirmed by surface expression analysis of T R 1-specific parameters, such as CD49b and LAG3 [35] . It remains to be elucidated which Treg subsets are exactly being induced by 1,25D 3 -DCs in vitro and in vivo. Moreover, the exact mechanisms by which 1,25D 3 -DCs induce antigen-specific Tregs to restore peripheral tolerance or immune homeostasis are still not fully understood. A crucial role for PD-L1, upregulated upon 1α,25(OH) 2 D 3 modulation of the DCs, has been reported as PD-L1 blockade resulted in Th1-like cells without suppressive capacity [10] . It is thought that increased PD-L1 triggers IL-10 production by the DCs, thereby driving Treg differentiation [36] . Moreover, 1,25D 3 -DCs produced elevated amounts of soluble TNF after maturation, but mTNF was shown to be essential for the induction of suppressive T cells through the mTNF-TNF receptor II signaling pathway [20] . Tolerogenic DCs expressing IDO promote immune tolerance since tryptophan depletion reduces T cell proliferation, while kynurenine pushes Treg differentiation via the aryl hydrocarbon receptor (AhR). In addition, low tryptophan levels increase ILT-3 and ILT-4 expression on human DCs [33] . Although ILT-3 expression by DCs is required to induce FoxP3 + Tregs, it is dispensable for Treg induction by 1,25D 3 -DCs [37] . Antigen-specific iTregs are believed to suppress diabetogenic Th1 cells via linked suppression and infectious tolerance [38] . In the present report, we showed that 1,25D 3 -DCs secrete IL-10 and were fully active in vitro and in vivo. The xenogeneic GVHD model in NSG mice provides the unique opportunity to test the functionality of human tolerogenic DCs in an in vivo situation. NSG mice are a model for immunodeficiency as these animals lack functional T cells, B cells and NK cells. Moreover, NSG mice do not express the IL-2Rγ resulting in defective cytokine signaling pathways [39] . In this mouse model, human PBMC transfer will cause GVHD due to the immune reaction of human T cells against murine tissues. The severity of the induced GVHD depends on the dose of PBMCs infused. Interestingly, infusion of enriched Tregs have been shown to delay the development of xenogeneic GVHD in NSG mice [40] . In the current study, the co-transfer of 1,25D 3 -DCs alongside human PBMCs could significantly delay xenogeneic GVHD, suggesting the induction of Tregs in this model and demonstrating the stability of the tolerogenic profile in the highly pro-inflammatory milieu in GVHD. Although we did not completely prevent GVHD, it would be interesting to study whether higher DC doses or repetitive dosing need to be explored. Our results indeed showed that the induction of Tregs in vivo is a transient phenomenon that probably requires multiple doses of 1,25D 3 -DCs to obtain a stable Treg population. Moreover, we believe that 1,25D 3 -DCs are a safer and more specific way to interfere with GVHD in the allo-BMT setting compared to general immunosuppression with pharmacologic inhibitors. This observation is also of great importance for the current application of 1,25D 3 -DCs in several autoimmune disorders, like type 1 diabetes (Trialregister.nl; NTR5542) and multiple sclerosis (MS) (Clinicaltrial.gov; NCT02903537 and NCT02618902). In these circumstances, monocytes from autoimmune patients are isolated, treated ex vivo with high doses of 1α,25(OH) 2 D 3 , and loaded with disease-relevant antigens (e.g. proinsulin in type 1 diabetes or myelin peptides in MS). Once the in vitro induction of the tolerogenic profile of these antigen-specific 1,25D 3 -DCs is confirmed, the cells are transferred back into the patients in order to induce Tregs specific for the antigens used. Our data indicate that it is highly unlikely that these cells would revert to an immunogenic phenotype and aggravate disease upon transfer into a proinflammatory environment in vivo
In conclusion, we verified the potential of 1α,25(OH) 2 D 3 to induce tolerogenic DCs, that remain stable when challenged with pro-inflammatory signals both in vitro and in vivo, strengthening the potential use of these 1,25D 3 -DCs for tolerance induction in autoimmune diseases and open therapeutic routes for the treatment of GVHD.
